Literature DB >> 2592507

Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization.

H Shioya1, M Shimojo, Y Kawahara.   

Abstract

A sensitive and specific gas chromatographic-mass spectrometric method for the simultaneous determination of angiotensin-converting enzyme inhibitor (I, CS-622) and its active desethyl metabolite (II, RS-5139) in plasma and urine was developed. Compound D5-RS-5139 was used as an internal standard and measurements were made by electron-capture negative ion chemical ionization. Extraction from plasma and urine was carried out using Sep-Pak C18 and silica cartridges. The extract of plasma or urine was treated with diazomethane followed by trifluoroacetic anhydride to convert I and II into their methyl ester trifluoroacetyl derivatives. The detection limit of I and II was 0.5 ng/ml in plasma and 5 ng/ml in urine. The proposed method was satisfactory for the determination of I and II in plasma and urine with respect to accuracy and precision. Thus it is suitable for measurement of bioavailability and pharmacokinetics of I and II in body fluids.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592507     DOI: 10.1016/s0378-4347(00)82559-1

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients.

Authors:  K Püchler; B Sierakowski; I Roots
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.

Authors:  M Nakashima; J Yamamoto; M Shibata; T Uematsu; H Shinjo; T Akahori; H Shioya; K Sugiyama; Y Kawahara
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function.

Authors:  S Furuta; K Kiyosawa; M Higuchi; H Kasahara; H Saito; H Shioya; H Oguchi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency.

Authors:  H Oguchi; M Miyasaka; T Koiwai; S Tokunaga; K Hora; K Sato; T Yoshie; H Shioya; S Furuta
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.